Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473236 · ClinicalTrials.gov registry record · Phase 1
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
A Phase 1 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03473236 is a Phase 1 study that has completed, run by GB002, Inc., a wholly owned subsidiary of Gossamer Bio. The registered enrollment target is 66 participants.
The verdict
NCT03473236, a Phase 1 study, has completed, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
Interventions
- DRUG Placebo
- DEVICE Generic Dry Powder Inhaler
- DRUG GB002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03473236
The ClinicalTrials.gov registry entry for NCT03473236 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03473236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03473236 about?
NCT03473236 is a clinical study titled "Phase 1A Safety Trial of Inhaled PK10571 (GB002)". This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
What is the current status of trial NCT03473236?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2017-09-06. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03473236?
The interventions under investigation include: Placebo (DRUG), Generic Dry Powder Inhaler (DEVICE), GB002 (DRUG).
Who is sponsoring clinical trial NCT03473236?
This trial is sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.